Lung cancer is mainly dominated by K-ras mutations, which enhance the self-amplification characteristics of NSCLC cancer cells through nuclear-transcribed gene activity and affect the clinical outcomes of patients [40, 41]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.